Results of MGMT-NET study

Through the publication of the MGMT-NET study in Journal of Clinical Oncology, I would like to acknowledge the Hospices Civils de Lyon team (the promotor), my colleagues (Catherine Lombard-Bohas, Alice Durand, Laura Gerard), the GTE and the Endocan-Renaten network, all the authors, and the patients and the French patient’s association (APTED).

Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).

Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; “Groupe d’étude des tumeurs endocrines (GTE)” and the French ENDOCAN-RENATEN network.J Clin Oncol. 2024 Nov 25:JCO2302724. doi: 10.1200/JCO.23.02724. Online ahead of print.PMID:?39586038

?